Sopheon has successfully navigated another COVID year with revenue of £34.4m, 4% ahead of original expectations and 14% ahead of the prior year. EBITDA guidance in January had been lifted 35%, with a further 2% revealed today, due in part to involuntary restraint on spending due to tight labour markets, but boosting free cash flow to $4.6m including expanded capitalised R&D at $4.7m (vs $4.0m in FY20). With growth now restored after the lockdown effects in 2020, the investment case is back to fo ....
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sopheon - Back to the future
- Published:
24 Mar 2022 -
Author:
Andrew Darley | Kimberley Carstens -
Pages:
16
Sopheon has successfully navigated another COVID year with revenue of £34.4m, 4% ahead of original expectations and 14% ahead of the prior year. EBITDA guidance in January had been lifted 35%, with a further 2% revealed today, due in part to involuntary restraint on spending due to tight labour markets, but boosting free cash flow to $4.6m including expanded capitalised R&D at $4.7m (vs $4.0m in FY20). With growth now restored after the lockdown effects in 2020, the investment case is back to fo ....